Costs of COPD in Sweden according to disease severity

被引:119
作者
Jansson, SA
Andersson, F
Borg, S
Ericsson, Å
Jönsson, E
Lundbäck, B
机构
[1] Karolinska Inst, Natl Inst Environm Med, Unit Lung & Allergy Res, SE-17177 Stockholm, Sweden
[2] Sunderby Cent Hosp Norrbotten, Dept Med, OLIN Studies, Lulea, Sweden
[3] Umea Univ, Dept Resp Med & Allergy, Umea, Sweden
[4] AstraZeneca R&D, Lund, Sweden
关键词
COPD; cost of illness; severity; Sweden;
D O I
10.1378/chest.122.6.1994
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: COPD is a common and disabling disease that entails high costs for society. The objectives of this study were to measure the societal costs of COPD in Sweden, and to examine the relationship between severity of illness and costs. Methods: The costs of COPD were examined using a well-defined and representative cohort of subjects with mild, moderate, and severe COPD. Regular telephone interviews regarding resource utilization were made to a cohort of 212 subjects with COPD derived from studies of the general population in Northern Sweden. Results: The annual per capita cost for COPD in Swedish crowns (SEK) was estimated at SEK 13,418 (1,284 US dollars (USD); 1,448 euros (EUR). The direct and indirect costs were SEK 5,592 (42%) and SEK 7,828 (58%), respectively. A highly significant relationship was found between severity of disease and costs. Costs for severe disease were 3 times as high as costs for moderate disease and > 10 times as high as for mild disease. Large individual variations in the level of costs were found. Conclusion: Assuming that the prevalence and treatment patterns are representative of Sweden as a whole, the total costs of COPD to society in 1999 were estimated at SEK 9.1 billion (USD 871 million; EUR 982 million). Subjects with mild disease (83%) accounted for 29%, while subjects with moderate disease (13%) accounted for 41% of the total costs. The subjects with severe disease (4%) accounted for the remainder (30%). Prevention, early diagnosis, and postponement of disease progression should have large monetary and policy implications.
引用
收藏
页码:1994 / 2002
页数:9
相关论文
共 44 条
[1]  
ANDERSSON F, 1995, BMJ EC, V8, P125
[2]   PREVALENCE OF OBSTRUCTIVE LUNG-DISEASE IN A GENERAL-POPULATION - RELATION TO OCCUPATIONAL TITLE AND EXPOSURE TO SOME AIRBORNE AGENTS [J].
BAKKE, PS ;
BASTE, V ;
HANOA, R ;
GULSVIK, A .
THORAX, 1991, 46 (12) :863-870
[3]  
Buist A. S., 1996, EUR RESPIR REV, V6, P253
[4]   HEALTH-RELATED QUALITY-OF-LIFE AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
CURTIS, JR ;
DEYO, RA ;
HUDSON, LD .
THORAX, 1994, 49 (02) :162-170
[5]   Muscle weakness is related to utilization of health care resources in COPD patients [J].
Decramer, M ;
Gosselink, R ;
Troosters, T ;
Verschueren, M ;
Evers, G .
EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (02) :417-423
[6]  
DOLL R, 1994, BRIT MED J, V149, P1218
[7]   Reliability and validity of a Swedish version of the St George's Respiratory Questionnaire [J].
Engstrom, CP ;
Persson, LO ;
Larsson, S ;
Sullivan, M .
EUROPEAN RESPIRATORY JOURNAL, 1998, 11 (01) :61-66
[8]   Patient self-reports in pharmacoeconomic studies - Their use and impact on study validity [J].
Evans, C ;
Crawford, B .
PHARMACOECONOMICS, 1999, 15 (03) :241-256
[9]  
*FASS, 1999, SWED PHARM
[10]  
Fletcher C, 1976, NATURAL HIST CHRONIC